1 / 18

Drug Coated Balloons From Bench to Bedside

Drug Coated Balloons From Bench to Bedside. Service de Radiodiagnostic et Radiologie Interventionnelle Université de Lausanne. Salah D. Qanadli , MD, PhD, FCIRSE Cardio-Thoracic and Vascular Unit, QMI Lab Department of Radiology CHUV-University of Lausanne. Potential Conflict of Interest.

ryu
Download Presentation

Drug Coated Balloons From Bench to Bedside

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug Coated BalloonsFrom Bench to Bedside Service de Radiodiagnostic et Radiologie Interventionnelle Université de Lausanne Salah D. Qanadli, MD, PhD, FCIRSE Cardio-Thoracic and Vascular Unit, QMI Lab Department of Radiology CHUV-University of Lausanne

  2. Potential Conflict of Interest • Educational grants • Cordis, Boston Scientific, Medtronic, Invatec, Bard • Research grants • Abbott Vascular, Biotronik, Cordis, St Jude Medical • Consultancy • Mediar Ltd. • University of Kingston London • Cook, Optimed, Cordis, Bard, Abbott, Terumo • Bioclinica

  3. Dotter’s Predictions in World’s First PTA* • Balloon angioplasty • Recanalization devices • Outpatient PTA • Cost saving relative to surgery • Endovascular “splints” (stents) that “reintimalize” (endothelialize) Dotter et al., Circulation, 1964

  4. PTA in 2013 for PAD • Critical issues • Immediate technical results • - Immediate out-come • Flow limiting dissection • Elastic Recoil • Immediate technical success • CTO recanalization • Re-stenosis (mid and long-term patency) DCB Technology

  5. DCB Mechanism of Action • 30-second minimum inflation transfers drug to endoluminal surface • PTX diffuses into the arterial wall from an endoluminal reservoir • Over time, therapeutic drug levels are sustained in deep cell layers after endothelial drug levels become sub-therapeutic • Drug continues to inhibit restenosis in arterial wall while allowing the lumen to restore and re-endothelialize

  6. LUTONIX Pre-clinical data

  7. Coating uniformity • European Product, Data on file. • 6x60 mm Lutonix Drug Coated Balloon – N=5 • 6x60 mm In.Pact Admiral-Paclitaxel-eluting PTA balloon catheter – N=5

  8. Defining Indications for DCB • Clinical needs • Device availability • Proof of concept • Clinical evaluation • Strategy for use/Cost-effectiveness

  9. Defining Indications for DCB • Clinical needs • Clinically driven concept • High risk of re-stenosis • Femoro-popliteal lesions • up to 60 % at 12 mo* • Small vessels BTK • up to 69%** • AV Dialysis access • Re-stenosis/occlusion up 62 % at 12 mo*** *Muradin GS et al., Radiology, 2001. **Krokidis M et al., CardiovascInterventRadiol, 2012. ***Bittl JA, JACC Cardiovascular Interv, 2010.

  10. Defining Indications for DCB • Clinical needs • Clinically driven concept • Limitations of existing alternatives (Stents, including DES) • BTK ? • BTA • AV shunts • FP • ISR • Complex anatomy (bifurcations, trans-collateral approaches,…) • Over dependence of double anti-agregants

  11. Defining Indications for DCB • Technology safety/efficacy • Proof of concept • Paclitaxel coated balloon (PCB) • DCB in routine practice in 2013 is PCB ! • Clinical evaluation • Level of Evidence • Cost-effectiveness • Strategy for use

  12. De-Novo Femoro-popliteal Lesions THUNDER FemPac LEVANT I PACIFIER Control arm: UB ! Median FU: 10.3 mo Exclusion: Severely impaired arterial out flow

  13. BTK Lesions

  14. AV Dialysis Access

  15. In-Stent Re-Stenosis

  16. Who is the best candidate for PCB ? BTK/BTA ISR AV Dialysis Access

  17. What doses the future hold ? BTK/BTA ISR AV Dialysis Access

  18. “Good judgment is based on experience and experience is based on bad judgment” Martin J. Lipton

More Related